Epidemiology Data Slicer
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
According to Clarivate epidemiology, more than 30 million people in the United States experience migraines. Migraine prophylaxis, despite being underused, is a core treatment approach to reduce the…
Migraine, which afflicts approximately 34 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Since 2018, four novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies (MAbs)—Novartis / Amgen’s Aimovig, Eli Lilly’s Emgality, Teva’s Ajovy, and Lundbeck’s Vyepti…
Triptans have long been the mainstay of acute treatment of migraine, but in Q1 2020, three novel oral nontriptans—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s Nurtec ODT…
Triptans have long been the mainstay of acute treatment of migraine, but in Q1 2020, three novel oral nontriptans—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s Nurtec ODT…